Holoxan (ifosfamide) 2000 mg for intravenous injection BAXTER Germany

Interchangeable drugs with the same active ingredient:

• Vero-Ifosfamide
• Vizfamid
• Ifolem
• ifos
• Ifosfamide
• Ifosfamide-Health
• Holoxan 1 G
• Holoxan 2 G
• Holoxan 500

Indications

testicular tumors

• As part of combination chemotherapy for patients with advanced stage II-IV tumors according to the TNM classification (International Classification of Malignant Tumors) (Semina and Nesemin), which did not respond sufficiently or did not respond at all to primary chemotherapy.

Cervical carcinoma (cervical carcinoma)

• Palliative combination chemotherapy with cisplatin/ifosfamide (without additional combination drugs) for cervical carcinoma, stage IV B according to the classification of the International Federation of Obstetrics and Gynecology (FIGO) (if definitive surgery or radiation therapy is not possible), as an alternative to palliative radiotherapy.

Mammary cancer

• As palliative therapy for advanced resistant or recurrent breast cancer.

Non-small cell bronchial carcinoma

• As monotherapy or as part of combination chemotherapy in patients with inoperable or metastatic tumors.

Small cell bronchial carcinoma

• As part of combination chemotherapy.

Soft tissue sarcoma (including osteosarcoma and rhabdomyosarcoma)

• As monotherapy or as part of combination chemotherapy for rhabdomyosarcoma or osteosarcoma when standard treatment is ineffective.
• As monotherapy or as part of combination chemotherapy for other soft tissue sarcomas with the ineffectiveness of surgical and radiation therapy.

Ewing's sarcoma

• As part of combined chemotherapy with the ineffectiveness of primary cytostatic therapy.

Non-Hodgkin's lymphoma

• As part of combination chemotherapy, patients with high-grade non-Hodgkin's lymphoma did not respond well or did not respond at all to primary therapy. As part of combination therapy for patients with recurrent tumors.

Hodgkin's disease

• For the treatment of patients with Hodgkin's disease, especially those with a progressive course or early relapse (duration of complete remission less than one year), after failure of primary chemotherapy or radiochemotherapy in combination chemotherapy regimens such as the MINE protocol.